The influencing factors of endocrine toxicity in patients with non-small cell lung cancer after treatment with pembrolizumab
Objective To investigate the influencing factors of endocrine toxicity in patients with non-small cell lung cancer(NSCLC)treated with pabolizumab.Methods Continuous cases of primary NSCLC hospitalized in the Second People's Hospital of Jincheng City from January 1,2020 to December 31,2022 who had received at least one course of pembrolizumab treatment were selected as the study objects.General data were collected.Patients with or without pembrolizumab related endocrine toxicity were divided into two groups,patients with endocrine toxicity as the case group,and patients without endocrine toxicity as the control group.Univariate analysis and multivariate Logistic regression analysis were used to determine the risk factors for endocrine toxicity after pembrolizumab treatment.Results A total of 153 cases were included in this study,of which 72 cases(47.06%)showed different levels of endocrine toxicity.Univariate analysis showed that there were significant differences between the case group and the control group in age,PD-L1 expression before treatment,duration of treatment,chemotherapy,targeted drugs,chemotherapy+targeted drugs(P＜0.05).Multivariate Logistic regression analysis showed that duration of treatment,low PD-L1 before treatment,targeted drugs,chemotherapy and chemotherapy+targeted drugs were risk factors for endocrine toxicity of pembrolizumab.Conclusion Duration of treatment,low PD-L1 level before treatment,targeted drugs,chemotherapy and chemotherapy+targeted drugs are the influencing factors for endocrine toxicity of pembrolizumab.
万方数据
维普
